JOURNAL OF PHARMA INSIGHTS AND RESEARCH ISSN NO. 3048-5428

REVIEW ARTICLE

Current Perspectives on Biopolymer-Based Injectable Formulations

Kaunain Fathema[1], R Surya Anusha Venna*[2], RVS Chaitanya Koppala[3], Sailaja Gunnam[4]

[1] *PG Scholar, Department of Pharmaceutics, Gokaraju Rangaraju College of Pharmacy, Hyderabad, Telangana, India*
[2] *Assistant Professor, Department of Pharmaceutics, Gokaraju Rangaraju College of Pharmacy, Hyderabad, Telangana, India*
[3] *Associate Professor, Department of Pharmacology, Sarojini Naidu Vanita Pharmacy Maha Vidyalaya, Secunderabad, Telangana, India*
[4] *Associate Professor, Department of Pharmaceutics, Gokaraju Rangaraju College of Pharmacy, Hyderabad, Telangana, India*

Publication history: Received on 18th July 2025; Revised on 26th Aug 2025; Accepted on 2nd September 2025

Article DOI: 10.69613/hf8xy835

Abstract: Parenteral drug delivery systems are critical for therapeutics with poor oral bioavailability or those requiring controlled, localized release. Natural polymers have gained significant attention as advanced excipients for these formulations. Their inherent biocompatibility, biodegradability, and structural similarity to biological macromolecules offer distinct advantages over synthetic counterparts. These biopolymers, including polysaccharides (e.g., alginate, hyaluronic acid, chitosan) and proteins (e.g., gelatin, collagen, silk fibroin), are fabricated into diverse injectable platforms such as in situ forming hydrogels, microparticles, and nanoparticle carriers. These systems facilitate sustained drug release, provide localized therapeutic action, and serve as scaffolds in regenerative medicine. The functional versatility of these polymers allows for chemical modification to create stimuli-responsive materials that release therapeutic payloads in response to specific physiological cues. Despite their promise, challenges related to batch-to-batch variability, potential immunogenicity, suboptimal mechanical properties, and difficulties in terminal sterilization persist. Current research focuses on developing purified, chemically modified biopolymers and hybrid systems that merge natural materials with synthetic counterparts or inorganic nanomaterials. These research efforts are paving the way for next-generation injectable therapies in areas including oncology, chronic inflammatory diseases, and tissue regeneration.

Keywords: Natural polymers; Injectable drug delivery; Biocompatibility; Hydrogels; Controlled release

1. Introduction

The parenteral route of administration is indispensable in modern medicine, providing a reliable method for delivering therapeutics that are otherwise compromised by enzymatic degradation or poor absorption in the gastrointestinal tract [1]. It is the standard for biologic drugs, such as monoclonal antibodies, peptides, and nucleic acids, and is essential for achieving rapid onset of action or localized treatment [2]. However, conventional injectable solutions often result in sharp pharmacokinetic profiles, with high peak concentrations (Cmax) that can lead to systemic toxicity, followed by rapid elimination that necessitates frequent, often painful, injections [3].

To overcome these limitations, polymer-based controlled release systems have been developed. These systems act as depots, releasing the therapeutic agent in a predictable manner over extended periods, thereby maintaining the drug concentration within the therapeutic window [4]. While synthetic polymers like poly(lactic-co-glycolic acid) (PLGA) are well-established and FDA-approved for such applications, they are not without drawbacks, including the generation of acidic byproducts upon degradation and potential inflammatory responses [5].

This has led to a pronounced shift toward natural polymers, or biopolymers. Sourced from plant, animal, or microbial origins, these materials such as hyaluronic acid, chitosan, alginate, and gelatin offer a compelling alternative [6]. Their primary advantage lies in their inherent biological properties: they are often biocompatible, biodegradable via enzymatic pathways, and structurally analogous to components of the human extracellular matrix (ECM) [7]. This biomimicry makes them particularly suitable for applications in tissue engineering, where they can actively support cell adhesion, proliferation, and differentiation [8]. Despite this potential, the translation of natural polymer-based injectables from the laboratory to the clinic is encumbered by significant challenges. These include inherent variability between batches, often inferior mechanical strength compared to synthetic analogues, and complexities associated with sterilization and purification [9]. This work highlights the current applications of natural polymers in injectable systems, analyzes their functional advantages and inherent limitations, and explores the emerging trends and chemical strategies driving their future development.

* Corresponding author: R Surya Anusha Venna

2. Classification of Natural Polymers for Injectable Systems

Natural polymers used in parenteral formulations are broadly categorized based on their chemical structure, primarily as polysaccharides or proteins.

2.1. Polysaccharide-Based Polymers

Polysaccharides are high-molecular-weight carbohydrates composed of monosaccharide units. Their abundant hydroxyl and carboxyl groups make them highly hydrophilic and amenable to chemical modification.

2.1.1. Chitosan

Chitosan is a linear, cationic polysaccharide derived from the alkaline deacetylation of chitin, a structural polymer found in crustacean shells and fungi [10]. Its properties are dictated by its molecular weight and degree of deacetylation (DD), which defines the number of free amine groups. The primary amine groups on the polymer backbone become protonated ($-NH^{3+}$) in acidic-to-neutral environments, giving it a strong positive charge. This polycationic nature allows it to form electrostatic complexes with anionic molecules, including drugs, plasmids, and siRNA, making it a prominent candidate for non-viral gene delivery [11]. This charge also promotes mucoadhesion and transient opening of tight junctions. Moreover, chitosan exhibits pH-responsive solubility, which is exploited in in situ gelling systems, such as those combining chitosan with beta-glycerophosphate, which are liquid at room temperature but gel rapidly at 37°C [12].

2.1.2. Alginate

Alginate is an anionic linear copolymer extracted from brown seaweed, composed of (1-4)-linked beta-D-mannuronic acid (M) and alpha-L-guluronic acid (G) monomers. The ratio and sequencing of these M and G blocks vary by source and dictate the polymer's properties. Specifically, the G-blocks form sterically favorable cavities that ionically crosslink upon exposure to divalent cations, most commonly calcium (Ca2+), in a mechanism famously known as the 'egg-box' model [13]. This crosslinking is gentle, rapid, and can be performed at physiological conditions, making alginate a foundational material for encapsulating sensitive biologics and living cells for tissue engineering depots [14]. Alginates with high G-content form strong, brittle gels, while high-M alginates form softer, more flexible gels.

2.1.3. Hyaluronic Acid

Hyaluronic acid (HA), or hyaluronan, is a non-sulfated glycosaminoglycan found ubiquitously in the native ECM, particularly in skin, cartilage, and synovial fluid [15]. It is a simple repeating disaccharide, but it plays complex roles in cell signaling, wound healing, and matrix organization. Its exceptional water-binding capacity (imparting viscoelasticity) has led to its widespread clinical use in orthopedics for viscosupplementation and in ophthalmology [16]. Critically, HA is a primary ligand for the CD44 receptor, which is often overexpressed on the surface of various cancer cells. This interaction is actively exploited to create HA-functionalized nanoparticles that actively target tumors via receptor-mediated endocytosis [17]. Its abundant functional groups (carboxyls, hydroxyls) also allow for versatile modification, such as methacrylation or thiolation, to create covalently crosslinkable hydrogels for regenerative medicine [18].

2.2. Protein-Based Polymers

Protein-based polymers offer biological functionality, often containing specific amino acid sequences that can interact with cells and direct biological responses.

2.2.1. Gelatin

Gelatin is derived from the acidic or alkaline hydrolysis of collagen, the most abundant protein in the ECM. This process denatures the triple-helix structure of collagen into random coils but preserves key biological motifs, most notably the Arg-Gly-Asp (RGD) sequences that promote cell adhesion via integrin binding [19]. Gelatin is known for forming thermoreversible hydrogels, which transition from a liquid sol to a physical gel upon cooling below 30-35°C (a coil-to-helix transition). However, these physical gels are unstable at body temperature (37°C). To create stable depots, gelatin is chemically modified, most commonly with methacryloyl groups to form gelatin methacryloyl (GelMA). GelMA is a photopolymerizable hydrogel that can be covalently crosslinked in the presence of a photoinitiator and light, allowing for precise spatial and temporal control over gelation [20].

2.2.2. Collagen

As the primary structural protein of the ECM, collagen provides the foundational scaffold for virtually all animal tissues. Its use in injectable formulations offers unparalleled biomimicry, not only providing physical support but also presenting specific binding sites for cell receptors that regulate adhesion, migration, and differentiation [21]. It can be formulated as neutralized, atelocollagen

solutions (collagen with immunogenic telopeptides removed) that self-assemble into fibrillar gels at 37°C, mimicking natural fibrillogenesis. Its principal drawback, however, is its animal origin (typically bovine or porcine), which carries significant risks of immunogenicity and pathogen transmission. This has spurred the development of recombinant human collagen to provide a safer, highly defined, and standardized alternative, albeit at a significantly higher cost [22].



Figure 2. Classification and Formulation of Natural Polymers for Injectable Systems

Table 1. Natural Polymers Used in Injectable Formulations

Polymer	Source	Properties	Applications in Injectables
Chitosan	Crustacean shells, fungi	Cationic, pH-responsive, mucoadhesive	In situ gels beta-glycerophosphate), non-viral gene delivery (nanoparticles), vaccine adjuvant.
Alginate	Brown seaweed	Anionic, ionically crosslinks with divalent cations (e.g., Ca^{2+})	Cell encapsulation, in situ forming depots, microspheres for protein delivery.
Hyaluronic Acid (HA)	Microbial fermentation, animal tissue	Anionic, viscoelastic, binds to CD44 receptor	Viscosupplementation, dermal fillers, targeted drug delivery (nanoparticles), regenerative scaffolds (e.g., GelMA).
Gelatin	Animal collagen (hydrolysis)	Thermoreversible gelation, contains RGD cell-binding motif	Photocrosslinkable hydrogels (GelMA), 3D bioprinting bio-inks, microspheres.
Collagen	Animal tissues (bovine, porcine), recombinant	High biomimicry, fibrillar self-assembly, cell-instructive	Regenerative scaffolds, wound healing depots, dermal fillers.
Silk Fibroin	*Bombyx mori* cocoons	High mechanical strength, slow/tunable degradation	Mechanically robust scaffolds for bone/cartilage, sustained-release depots.
Albumin	Human/bovine plasma, recombinant	Natural carrier protein, long half-life	Nanoparticle drug delivery (e.g., Abraxane), passive and active tumor targeting.

2.2.3. Silk Fibroin

Derived from *Bombyx mori* (silkworm) cocoons after removal of the immunogenic sericin protein, silk fibroin is a unique block copolymer protein. It is renowned for its remarkable mechanical strength, toughness, and slow, tunable degradation rate, properties that are rare in biopolymers [23]. Unlike most soft natural hydrogels, crosslinked silk fibroin systems can be engineered to match the mechanical properties of stiffer tissues, such as cartilage or bone. Injectable formulations are typically prepared as aqueous silk fibroin solutions that can be induced to gel in situ. This gelation involves a conformational transition from a random coil to a mechanically robust beta-sheet crystalline structure, a process that can be controlled by factors like sonication, pH, or ion concentration [24].

2.2.4. Albumin

Albumin is the most abundant plasma protein in human blood, responsible for maintaining oncotic pressure and transporting a wide array of endogenous and exogenous molecules. Its long circulatory half-life (approx. 19 days) and natural carrier functions make it an ideal biopolymer for drug delivery [25]. This has been most successfully harnessed in the formulation of paclitaxel-bound albumin nanoparticles (Abraxane). These nanoparticles leverage the enhanced permeability and retention (EPR) effect for passive tumor targeting. Moreover, they are thought to engage the gp60 albumin receptor (albondin) on endothelial cells, triggering transcytosis and facilitating drug transport from the bloodstream into the tumor interstitium [26].

3. Mechanistic Platforms for Biopolymer-Based Injectables

Natural polymers are not merely inert carriers; they are functional materials used to create sophisticated delivery platforms that control the spatial and temporal release of therapeutics.

3.1. *In Situ* Forming Depots

A major advancement in injectable technology is the development of in situ forming systems. These are administered as low-viscosity liquids that undergo a sol-gel transition at the injection site, forming a semi-solid depot that conforms to the surrounding tissue [27]. This approach improves patient comfort and allows for the encapsulation of drugs or cells in a minimally invasive manner.

3.1.1. Physically Crosslinked Systems

These systems rely on reversible, non-covalent interactions to form a gel. The gelation can be triggered by a change in environmental conditions. Thermally-responsive hydrogels, such as the chitosan beta-glycerophosphate system [12] or synthetic block copolymers like Poloxamers (Pluronics), are low-viscosity liquids at room temperature but gel rapidly at 37°C. Ionically-crosslinked systems, exemplified by alginate, are injected simultaneously with or into a solution containing divalent cations (e.g., Ca^{2+}) to trigger 'egg-box' complexation and subsequent gelation [13]. Other physical mechanisms include self-assembly of peptide amphiphiles or stereocomplexation between polymer chains.

Table 2. Comparison of Mechanistic Platforms for Biopolymer-Based Injectables.

Platform	Mechanism	Polymers	Primary Function	Release Profile
In Situ Gels (Physical)	Sol-gel transition triggered by temperature, pH, or ions.	Chitosan, Alginate, Poloxamers	Forms a localized, conformable drug depot.	Sustained release (days to weeks) governed by diffusion and/or depot dissolution.
In Situ Gels (Covalent)	Sol-gel transition via chemical reaction (e.g., click chemistry, enzyme).	Modified HA, GelMA, Fibrin	Forms a stable, mechanically robust depot or scaffold.	Long-term sustained release (weeks to months) governed by matrix degradation.
Microspheres	Solid polymer particles (1-1000 microns in suspension.	Alginate, PLGA, Gelatin	Long-acting injectable (LAI) depot for systemic or local release.	Biphasic: Initial burst followed by zero or first-order release (weeks to months).
Nanoparticles	Solid/matrix particles (<1000 nm) in suspension.	Chitosan, HA, Albumin	Systemic delivery, passive/active tumor targeting, intracellular delivery.	Release is often coupled with particle uptake, endosomal escape, and degradation.
Regenerative Scaffolds	Bioactive hydrogels (often in situ forming) that mimic the ECM.	Collagen, Gelatin, HA	Provides 3D support and biological cues for tissue repair.	Delivers entrapped cells or growth factors locally as the scaffold degrades

3.1.2. Covalently Crosslinked Systems

Covalent crosslinking forms irreversible chemical bonds, providing more mechanically robust and stable depots with tunable degradation rates. Photocrosslinking, using materials like GelMA, offers exceptional spatial and temporal control but is limited by the penetration depth of light, restricting it to superficial applications [20]. Enzymatically-crosslinked systems are gaining traction as a highly biocompatible alternative. For example, horseradish peroxidase (HRP) and low concentrations of hydrogen peroxide (H_2O_2) can be used to catalyze the crosslinking of phenol-modified polymers like tyramine-substituted HA or gelatin [28]. 'Click chemistry,' such as the reaction between maleimide-functionalized and thiol-functionalized polymers, offers another rapid, highly specific, and bio-orthogonal method for in vivo gelation without cytotoxic reagents or catalysts [29].

3.2. Particulate Carrier Systems

Particulate systems encapsulate the drug within a solid polymer matrix, which is then suspended in an injectable vehicle.

3.2.1. Microspheres

Microspheres (typically 1-1000 microns) are solid, spherical particles designed for sustained release over weeks to months, often used for long-acting injectables (LAIs). They are commonly fabricated using emulsion-based techniques (e.g., water-in-oil emulsion) or spray drying. The drug is released in a biphasic manner: an initial burst release of surface-adsorbed drug, followed by a slower, sustained release controlled by drug diffusion through the polymer matrix and erosion of the polymer itself [30]. Alginate microspheres, formed by dropping an alginate-drug solution into a calcium bath, are a common platform for encapsulating large, sensitive biologic proteins, protecting them from in vivo degradation [31].

3.2.2. Nanoparticles

Nanoparticles (typically < 1000 nm, often 100-200 nm for systemic delivery) are engineered for more complex delivery tasks. Unlike microspheres, which typically form a local depot, nanoparticles are small enough to circulate in the bloodstream, enabling systemic delivery. They can extravasate into tissues with leaky vasculature, such as solid tumors, via the EPR effect [32]. They are also capable of being taken up by cells (endocytosis). Chitosan nanoparticles are widely studied for intracellular delivery of genes and siRNA. Their positive charge facilitates binding to the anionic cell membrane, promotes endocytosis, and buffers the endosome, leading to 'proton sponge'-mediated endosomal escape and cytosolic release [33].



Figure 3. Types of Injectable Formulations

3.3. Biologically-Interactive Systems

These advanced systems leverage the inherent biological activity of the natural polymer to achieve a specific therapeutic goal beyond simple drug release.

3.3.1. Active Targeting Platforms

These systems enhance therapeutic specificity by actively binding to cell-surface markers. This 'lock-and-key' interaction is achieved by functionalizing the polymer or nanoparticle surface with targeting ligands. In some cases, the polymer itself is the ligand; the intrinsic affinity of HA for the CD44 receptor is a prime example of this [17]. In other cases, polymers like chitosan or gelatin are

chemically conjugated with specific biomolecules, such as monoclonal antibodies (e.g., anti-HER2), antibody fragments, or peptides (e.g., RGD), that specifically bind to receptors overexpressed on diseased cells. This concentrates the therapeutic payload at the target site, enhancing efficacy and minimizing off-target toxicity [34].

3.3.2. Immune Modulatory Systems

Biopolymers can also function as active immune-stimulating adjuvants, not just inert carriers. Certain polysaccharides act as pathogen-associated molecular patterns (PAMPs). Chitosan and alginate microparticles, for instance, are recognized by pattern recognition receptors (PRRs) on antigen-presenting cells (APCs) like dendritic cells and macrophages [35]. This recognition, combined with the particulate nature (which promotes phagocytosis), activates the APCs. When co-administered with a vaccine antigen, these particles can promote APC maturation, cytokine secretion, and a more robust, skewed T-cell immune response, making them effective platforms for next-generation vaccine delivery [36].

3.3.3. Regenerative Scaffolds

In tissue engineering, injectable biopolymer hydrogels act as 3D scaffolds that mimic the native ECM, providing a hydrated, permissive environment for cell survival and tissue formation [8]. These scaffolds range from bio-inert (providing only physical support) to bioactive. Bioactive scaffolds, such as RGD-containing gelatin or collagen, provide cell-instructive cues that promote cell adhesion and signaling. These systems are designed to be temporary, degrading at a rate that matches new tissue formation. Moreover, they can be loaded with growth factors (e.g., bone morphogenetic protein-2, BMP-2) to actively direct tissue regeneration in bone or cartilage defects [37].

4. Advantages and Inherent Limitations of Natural Polymers

The utility of biopolymers is defined by a balance of significant advantages and persistent challenges.

4.1. Biological and Physicochemical Advantages

4.1.1. Biocompatibility and Biomimicry

Derived from biological sources, these polymers often exhibit excellent biocompatibility, as the body possesses metabolic pathways for their components. This can lead to minimal inflammatory or chronic foreign body responses compared to synthetic implants. Materials like collagen, gelatin, and HA are not just biocompatible but biomimetic. They present recognizable chemical and physical cues to cells, such as the RGD-sequence in gelatin or the CD44-binding sites on HA, allowing them to integrate seamlessly with host tissues and actively participate in biological processes [38].

4.1.2. Biodegradability

Natural polymers are typically degraded by specific endogenous enzymes (e.g., hyaluronidase for HA, proteases and collagenases for gelatin/collagen) into non-toxic, readily metabolizable byproducts. This enzymatic degradation is often more predictable and less inflammatory than the bulk or surface erosion of synthetic polyesters (like PLGA), which degrade by non-specific hydrolysis and release acidic monomers that can lower local pH and irritate tissue. This "smart" degradation avoids chronic inflammation and obviates the need for a second surgery to remove the implant [39].

4.1.3. Chemical Versatility

The abundance of reactive functional groups on biopolymer backbones such as hydroxyls (-OH) on polysaccharides, amines ($-NH_2$) on chitosan, and carboxyls (-COOH) on alginate and HA provides a rich chemical toolbox for modification. These groups serve as handles for covalent crosslinking to tune mechanical properties and degradation rates. They can also be used to conjugate targeting ligands, imaging agents, or other polymers, creating sophisticated hybrid materials with precisely tailored, multifunctional properties [40].

4.1.4. Abundance and Sustainability

Many biopolymers are sourced from abundant, renewable, and often low-cost resources. This includes agricultural products (e.g., starch) or industrial waste streams. Chitosan is derived from crustacean shell waste from the seafood industry, alginate is harvested from plentiful brown seaweed, and gelatin is a byproduct of the meat and leather industries [41]. This sourcing makes them not only potentially cost-effective but also aligns with 'green chemistry' and sustainability goals, a growing priority in pharmaceutical manufacturing.

Table 3. Advantages and Limitations of Natural Polymers in Injectables

Aspect	Advantages	Limitations & Challenges
Biological	Biocompatibility: Often low immunogenicity and inflammation. Biomimicry: Structurally similar to ECM; can be cell-instructive (e.g., RGD motifs).	Immunogenicity: Risk of allergic reactions (esp. animal proteins); removal of endotoxins and impurities is critical.
Degradation	Biodegradability: Degraded by specific enzymes into non-toxic, metabolizable products.	Uncontrolled Degradation: Can degrade too quickly in vivo; enzyme levels vary between patients.
Mechanical	Softness/Viscoelasticity: Properties are ideal for soft tissue augmentation and mimicking soft ECM.	Mechanical Insufficiency: Often weak, brittle, and unsuitable for load-bearing applications (e.g., bone).
Chemical	Functional Versatility: Abundant functional groups (-OH, -NH_2, -COOH) allow for easy modification.	Crosslinking: Chemical crosslinkers can be cytotoxic; modifications may mask bioactive sites.
Sourcing & Cost	Abundance: Sourced from renewable, low-cost raw materials or industrial byproducts.	Batch-to-Batch Variability: Properties (MW, purity, DD) vary significantly with source and extraction method.
Processing	Aqueous Processing: Most are water-soluble, avoiding the need for harsh organic solvents.	Sterilization: Highly sensitive to heat (autoclave) and radiation, often requiring costly aseptic processing.

4.2. Significant Challenges and Research Gaps

4.2.1. Batch-to-Batch Variability

This is arguably the most significant hurdle for clinical translation and commercialization. The physicochemical properties of natural polymers such as molecular weight, polydispersity, purity, and chemical structure (e.g., degree of deacetylation for chitosan or M/G ratio for alginate) can vary dramatically depending on the biological source (species, age, season) and the extraction/purification method [42]. This variability directly impacts gelation kinetics, mechanical strength, drug release profiles, and degradation. This lack of consistency complicates formulation reproducibility, device performance, and navigating the stringent regulatory approval process, which demands high reproducibility.

4.2.2. Mechanical Insufficiency

Many natural polymer hydrogels, due to their high-water content (often >95%) and physically crosslinked nature, are mechanically weak and exhibit poor structural integrity. Unmodified alginate or gelatin hydrogels, for example, are soft, brittle, and may degrade or dissolve too quickly in vivo to be effective for long-term applications [43]. This mechanical insufficiency makes them unsuitable for load-bearing tissues like bone or cartilage, which require robust, elastic scaffolds. While chemical crosslinking improves strength, it can sometimes reduce biocompatibility or cell-interactive properties.

4.2.3. Sterilization Difficulties

Injectable formulations require terminal sterilization to achieve a specific sterility assurance level (SAL). Natural polymers, however, are highly sensitive to standard sterilization methods. Autoclaving (steam heat) causes hydrolysis, leading to chain scission and a dramatic loss of viscosity and mechanical strength. Gamma irradiation, while more penetrating, can induce unpredictable chain scission and/or crosslinking, fundamentally altering the polymer's properties [44]. Ethylene oxide, while effective for dry materials, is a toxic gas and requires extensive degassing. Consequently, formulations often require costly aseptic processing (manufacturing in a sterile environment), which is complex, expensive, and less preferred by regulatory agencies than terminal sterilization.

4.2.4. Potential Immunogenicity

While generally considered biocompatible, materials from non-human sources, particularly proteins like bovine collagen or gelatin, carry an inherent risk of eliciting an immune or allergic response [45]. Even highly purified polysaccharides can be problematic. A significant challenge is the removal of process-related impurities, such as bacterial endotoxins (lipopolysaccharides from gram-negative bacteria) or residual proteins and DNA from microbial or animal sources. These impurities are highly pyrogenic and can trigger severe inflammatory reactions, necessitating stringent, expensive, and complex purification protocols to meet regulatory limits.

Table 4. Impact of Sterilization Methods on Injectable Natural Polymer Formulations

Sterilization Method	Mechanism	Effect on Natural Polymers	Suitability
Autoclaving (Steam Heat)	High temperature (121°C) and pressure.	Causes extensive hydrolysis of glycosidic and peptide bonds. Leads to chain scission, loss of molecular weight, and loss of gelation/mechanical properties.	Unsuitable for most biopolymer hydrogels and solutions.
Gamma Irradiation	High-energy photons induce ionization.	Causes unpredictable, dose-dependent chain scission and/or crosslinking. Can degrade polymer backbone and alter functional groups.	Case-by-case basis. Sometimes used for dry powders, but effects on hydrogels are often detrimental.
Ethylene Oxide (EtO) Gas	Chemical alkylation of proteins and nucleic acids.	Effective for dry, porous materials. However, EtO is toxic and a carcinogen; extensive degassing is required, which is difficult for hydrogels.	Limited use. Primarily for dry materials; not suitable for terminally-filled liquid formulations.
Sterile Filtration	Physical removal of microbes (0.22 micron filter).	Non-destructive to the polymer itself.	Suitable for polymer solutions *before* gelation or crosslinking. Cannot be used for particulate suspensions or highly viscous solutions.
Aseptic Processing	Manufacturing the product from sterile components in a sterile environment.	No direct impact on polymer properties.	Gold standard for sensitive biopolymer formulations, but is complex, expensive, and has a lower sterility assurance level (SAL) than terminal sterilization.

5. Current Trends

Research is actively focused on overcoming the limitations of natural polymers through chemical modification, hybrid material design, and advanced fabrication techniques.

5.1. Hybrid and Composite Systems

To enhance mechanical properties, biopolymers are increasingly combined with other materials. Hybrid hydrogels that form interpenetrating networks (IPNs) of a natural polymer (like alginate) and a synthetic polymer (like polyethylene glycol, PEG) can achieve a synergistic combination of biocompatibility and mechanical toughness [46]. Alternatively, nanocomposite hydrogels are being developed. In these systems, nanofillers such as bioactive glass, carbon nanotubes, or 2D nanosilicates (nanoclay) are incorporated into the biopolymer matrix. These nanoparticles act as physical crosslinkers, interacting with the polymer chains to significantly improve stiffness, toughness, and recovery after shear [47].

5.2. Advanced Drug Delivery Platforms

The inherent properties of biopolymers are being leveraged for 'smart' delivery systems. Hydrogels are being designed to respond to specific stimuli in the disease microenvironment. For example, systems can be engineered with acid-labile bonds that break in the low pH of a solid tumor or endosome, or with crosslinks that are cleaved by enzymes (like matrix metalloproteinases, MMPs) that are overexpressed in cancer [48]. Moreover, the development of safe and effective non-viral vectors for gene therapy remains a critical goal. Modified chitosan, functionalized HA, and other polysaccharides are at the forefront of this research, being engineered to protect nucleic acids (pDNA, siRNA) from nuclease degradation and facilitate their efficient intracellular delivery [49].

5.3. Regenerative Medicine and 3D Bioprinting

The future of regenerative medicine lies in fabricating patient-specific tissues. Injectable biopolymer hydrogels are foundational to this field, acting as 'bio-inks' for 3D bioprinting [50]. Materials like GelMA, alginate, and modified HA-based inks possess the necessary shear-thinning and rapid crosslinking properties to be printed layer-by-layer, along with living cells and growth factors, into complex, functional tissue constructs. The development of injectable, self-healing hydrogels, which are held together by dynamic, reversible bonds (e.g., guest-host chemistry or dynamic covalent bonds), is also a key area. These materials can reform after shear-thinning during injection, allowing them to fill irregularly shaped tissue defects in a minimally invasive manner [51].

5.4. Standardization and Recombinant Polymers

To solve the critical problem of batch-to-batch variability, there is a strong movement toward advanced standardization and the use of recombinant-DNA technology. Producing recombinant human collagen or gelatin in yeast or bacterial systems yields a product that is highly pure, non-immunogenic, and chemically defined (i.e., monodisperse molecular weight and precise amino acid sequence) [52]. This approach eliminates the risks of animal-derived pathogens and provides unparalleled control over the material's properties. While currently expensive, recombinant production represents the future for high-performance, clinically reliable biopolymer-based medical devices where lot-to-lot consistency is paramount.

6. Conclusion

Natural polymers are a cornerstone of innovation in modern injectable drug delivery and regenerative medicine. Their intrinsic biocompatibility, biodegradability, and functional versatility allow for the design of sophisticated systems from in situ forming depots to targeted nanoparticles and 3D-bioprinted scaffolds. These materials are transitioning from simple excipients to active therapeutic components. However, widespread clinical translation is currently tempered by critical challenges, most notably batch-to-batch variability, mechanical weakness, and difficulties in sterilization. The future of the field lies in overcoming these hurdles through the development of purified, recombinant biopolymers, and the creation of advanced hybrid and composite materials.

References

[1] Strickley RG. Solubilizing excipients in oral and injectable formulations. Pharm Res. 2004 Feb;21(2):201-30.

[2] Mitragotri S, Burke PA, Langer R. Overcoming the challenges in administering protein therapeutics. Nat Rev Drug Discov. 2014 Sep;13(9):655-72.

[3] Panchal K, Katke S, Dash SK, Gaur A, Shinde A, Saha N, et al. An expanding horizon of complex injectable products: development and regulatory considerations. Drug Deliv Transl Res. 2023 Feb;13(2):433-72.

[4] Lee JH, Yeo Y. Controlled drug release from pharmaceutical nanocarriers. Chem Eng Sci. 2015 Jan;125:75-84.

[5] Makadia HK, Siegel SJ. Poly Lactic-co-Glycolic Acid (PLGA) as a biodegradable controlled drug delivery carrier. Polymers (Basel). 2011 Sep;3(3):1377-97.

[6] Bhatia S, editor. Natural polymer drug delivery systems. Basel: Springer International Publishing; 2016.

[7] Vasile C, Pamfil D, Stoleru E, Baican M. New developments in medical applications of hybrid hydrogels containing natural polymers. Molecules. 2020 Mar 27;25(7):1539.

[8] Slaughter BV, Khurshid SS, Fisher OZ, Khademhosseini A, Peppas NA. Hydrogels in regenerative medicine. Adv Mater. 2009 May 4;21(32-33):3307-29.

[9] Catoira MC, Fusaro L, Di Francesco D, Ramella M, Boccafoschi F. Overview of natural polymers used in regenerative medicine applications. J Tissue Eng Regen Med. 2019 Sep;13(9):1539-60.

[10] Rinaudo M. Chitin and chitosan: Properties and applications. Prog Polym Sci. 2006 Jul;31(7):603-32.

[11] Ragelle H, Vandermeulen G, Préat V. Chitosan-based nanoparticles for gene delivery. J Control Release. 2013 Aug 28;172(1):167-78.

[12] Chenite A, Chaput C, Wang D, Combes C, Buschmann MD, Selmani A, et al. Novel injectable neutral solutions of chitosan form biodegradable gels in situ. Biomaterials. 2000 Mar;21(21):2155-61.

[13] Grant GT, Morris ER, Rees DA, Smith PJ, Thom D. Biological interactions between polysaccharides and divalent cations: The egg-box model. FEBS Lett. 1973 Mar 12;32(1):195-8.

[14] Lee KY, Mooney DJ. Alginate: Properties and biomedical applications. Prog Polym Sci. 2012 Jan;37(1):106-26.

[15] Fraser JRE, Laurent TC, Laurent UBG. Hyaluronan: its nature, distribution, functions and turnover. J Intern Med. 1997 Jul;242(1):27-33.

[16] Bowman S, Awad ME, Hamrick MW, Hunter M, Fulzele S. Recent advances in hyaluronic acid based therapy for osteoarthritis. Clin Transl Med. 2018 Feb 19;7(1):6.

[17] Mizejewski GJ. Hyaluronan and CD44-receptor interaction as a target for cancer therapy: an updated review. Cancers (Basel). 2023 Jul 26;15(15):3846.

[18] Burdick JA, Prestwich GD. Hyaluronic acid hydrogels for biomedical applications. Adv Mater. 2011 May 24;23(12):H41-56.

[19] Bello AB, Kim D, Kim S, Park H, Lee SH. Cell-adhesion and protein-adsorption properties of RGD-grafted gelatin methacryloyl hydrogels. Gels. 2020 Sep 28;6(4):30.

[20] Van Den Bulcke AI, Bogdanov B, De Rooze N, Schacht EH, Cornelissen M, Berghmans H. Structural and rheological properties of methacrylamide modified gelatin hydrogels. Biomacromolecules. 2000 Sep;1(3):31-8.

[21] Ferreira AM, Gentile P, Chiono V, Ciardelli G. Collagen for bone tissue regeneration. Acta Biomater. 2012 Sep;8(9):3191-200.

[22] Shoseyov O, Posen Y, Gdalevsky G. Recombinant human collagen: from a advanced biomaterial to a component of cultivated meat. npj Sci Food. 2024 Mar 16;8(1):17.

[23] Rockwood DN, Preda RC, Yücel T, Wang X, Lovett ML, Kaplan DL. Materials fabrication from Bombyx mori silk fibroin. Nat Protoc. 2011 Sep;6(10):1612-31.

[24] Lu Q, Huang H, Wang X, Hu K, Kaplan DL. In vitro and in vivo degradation of silk fibroin-based hydrogels. Biomaterials. 2012 Jun;33(18):4515-23.

[25] Paal K, Müller J, Hegedűs L. Albumin as a transport protein for therapeutics. J Control Release. 2021 Nov;339:239-58.

[26] Gradishar WJ. Albumin-bound paclitaxel: a next-generation taxane. Expert Opin Pharmacother. 2006 May;7(8):1041-53.

[27] Yu C, Yao F, Li J. Rational design of injectable conducting polymer-based hydrogels for tissue engineering. Acta Biomater. 2022 Feb 1;139:4-21.

[28] Jin R, Lin B, Karuthedath S, He W, Thomas V. Tyramine-modified gelatin-hyaluronic acid hydrogel crosslinked by horseradish peroxidase for cartilage tissue engineering. J Biomed Mater Res A. 2019 Jul;107(7):1445-56.

[29] Hu W, Wang Z, Xiao Y, Zhang S, Wang J. A review of bio-orthogonal click chemistry in macro-biomolecule modification and its applications. RSC Adv. 2019;9(40):23438-50.

[30] Ye Q, Asherman J, Stevenson M, Brown J, Tresco P. Sustained release of bioactive proteins from calcium alginate microspheres. J Control Release. 2000 Aug 28;68(1):117-25.

[31] Gombotz WR, Wee SF. Protein release from alginate matrices. Adv Drug Deliv Rev. 1998 May 18;31(3):267-85.

[32] Maeda H, Wu J, Sawa T, Matsumura Y, Hori K. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J Control Release. 2000 Jan 3;65(1-2):271-84.

[33] Al-Dosari MS, Gao X. Nonviral gene delivery: principle, limitations, and recent progress. AAPS J. 2009 Dec;11(4):671-81.

[34] Torchilin VP. Multifunctional nanocarriers. Adv Drug Deliv Rev. 2006 Dec 7;58(14):1532-55.

[35] Zgurskaya HI. Multidrug resistance: PAMPs, PRRs, and beyond. Future Microbiol. 2009 Nov;4(9):1097-105.

[36] Demento SL, Siefert AL, Bandyopadhyay A, Sharp FA, Fahmy TM. Pathogen-associated molecular patterns on biomaterials: a paradigm for engineering new vaccines. Trends Biotechnol. 2011 Jul;29(7):315-26.

[37] Lee K, Silva EA, Mooney DJ. Growth factor delivery-based tissue engineering: general approaches and a case study for angiogenesis. J R Soc Interface. 2011 Jan 6;8(54):153-70.

[38] Yue K, Trujillo-de Santiago G, Alvarez-Segura M, Alvarez MM, C M, Zhang YS, et al. Synthesis, properties, and biomedical applications of gelatin methacryloyl (GelMA) hydrogels. Biomaterials. 2015 Dec;73:254-71.

[39] Li J, Mooney DJ. Designing hydrogels for controlled drug delivery. Nat Rev Mater. 2016 Sep 20;1(12):16071.

[40] Van Vlierberghe S, Dubruel P, Schacht E. Biopolymer-based hydrogels as scaffolds for tissue engineering applications: a review. Biomacromolecules. 2011 May 13;12(5):1387-408.

[41] Ali G, Sharma M, Salama ES, Ling Z, Li X. Applications of chitin and chitosan as natural biopolymer: potential sources, pretreatments, and degradation pathways. Biomass Convers Biorefinery. 2024 Feb;14(4):4567-81.

[42] Park S, Hideshima S, Kuroiwa T, Nishi N, Oishi Y, Shirai Y. Effect of batch-to-batch variation of chitosan on the preparation and properties of polyelectrolyte complexes with gellan gum. J Appl Polym Sci. 2011 Sep 15;121(6):3268-74.

[43] Almawash S, Osman SK, Mustafa G, El Hamd MA. Current and future prospective of injectable hydrogelsdesign challenges and limitations. Pharmaceuticals (Basel). 2022 Mar 18;15(3):371.

[44] Morent R, De Geyter N, Desmet T, Dubruel P, Leys C. Plasma surface modification of biopolymers. Plasma Process Polym. 2011 Mar;8(3):171-90.

[45] Gorgieva S, Kokol V. Collagen- vs. gelatine-based biomaterials and their biocompatibility: review and perspectives. Biomater Appl Nanomed. 2011;17:42.

[46] Maitra J, Shukla VK. Cross-linking in hydrogels - A review. Am J Polym Sci. 2014;4(2):25-31.

[47] Gaharwar AK, Peppas NA, Khademhosseini A. Nanocomposite hydrogels for biomedical applications. Biotechnol Bioeng. 2014 Mar;111(3):441-53.

[48] Hu Q, Katti PS, Gu Z. Enzyme-responsive nanomaterials for controlled drug delivery. Nanoscale. 2014;6(21):12273-86.

[49] Karayianni M, Sentoukas T, Skandalis A, Pippa N, Pispas S. Chitosan-based nanoparticles for nucleic acid delivery: technological aspects, applications, and future perspectives. Pharmaceutics. 2023 Jun 29;15(7):1849.

[50] Murphy SV, Atala A. 3D bioprinting of tissues and organs. Nat Biotechnol. 2014 Aug;32(8):773-85.

[51] Taylor DL, in het Panhuis M. Self-healing hydrogels. Adv Mater. 2016 Aug;28(41):9060-93.

[52] Olsen D, Yang C, Bodo M, Chang R, Leigh S, Baez J, et al. Recombinant collagen and gelatin for drug delivery and tissue engineering. Adv Drug Deliv Rev. 2003 Nov 28;55(12):1547-67.